SEHK:2268Life Sciences
WuXi XDC Cayman (SEHK:2268) Margin Slip Tests Bullish Growth Narrative After FY 2025 Earnings
WuXi XDC Cayman (SEHK:2268) has posted FY 2025 results that put the focus squarely on scale, with second half revenue of C¥3.2b and basic EPS of C¥0.60, underpinned by trailing twelve month revenue of C¥5.9b and EPS of C¥1.22. The company has seen revenue move from C¥2.4b in the second half of 2024 to C¥3.2b in the second half of 2025, with basic EPS over that period shifting from C¥0.48 to C¥0.60 as investors weigh a trailing net margin of 24.9% against a slightly lower level a year ago.
See...